Drug intelligence / Profile preview

ALAnerv ON

Development stage: Unknown
Lead developer: Alfasigma
Modality: Small Molecules
Administration: Oral

Overview

ALAnerv ON is a multi-ingredient dietary supplement developed by Alfasigma (formerly Alfa Wassermann) designed to support the nervous system and protect against oxidative stress. It is primarily used as an adjunct in the management of peripheral neuropathies, such as carpal tunnel syndrome and radiculopathy. The formulation contains alpha-lipoic acid (ALA), a powerful antioxidant; gamma-linolenic acid (GLA), an essential fatty acid; honokiol, a polyphenolic compound derived from Magnolia bark with anti-inflammatory properties; and a complex of B-group vitamins (B1, B2, B5, B6), Vitamin E, and Selenium. Together, these components work synergistically to reduce nerve inflammation, improve nerve conduction, and neutralize free radicals.

Brand names: ALAnerv ON

Beyond the preview

Go deeper on ALAnerv ON.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALAnerv ON.

Explore the full profile